Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes

Goldstein, Steven R; Neven, Patrick; Cummings, Steven; Colgan, Terence; Runowicz, Carolyn D; Krpan, Dalibor; Proulx, James; Johnson, Margot; Thompson, David; Thompson, John; Sriram, Usha

doi:10.1097/gme.0b013e3181e84bb4

Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes

Author:

Goldstein, Steven R

Neven, Patrick ; Cummings, Steven ; Colgan, Terence ; Runowicz, Carolyn D ; Krpan, Dalibor ; Proulx, James ; Johnson, Margot ; Thompson, David ; Thompson, John ; Sriram, Usha

Keywords:

Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Middle Aged, Osteoporosis, Postmenopausal, Ovarian Cysts, Ovarian Neoplasms, Polyps, Postmenopause, Proportional Hazards Models, Pyrrolidines, Selective Estrogen Receptor Modulators, Tetrahydronaphthalenes, Urinary Incontinence, Uterine Diseases, Uterus, Science & Technology, Life Sciences & Biomedicine, Obstetrics & Gynecology, Lasofoxifene, Postmenopausal, Endometrial, Cancer, Hyperplasia, Gynecologic, BREAST-CANCER, WOMEN, RALOXIFENE, BONE, PREVENTION, TAMOXIFEN, UTERUS, Ultrasonography, 11 Medical and Health Sciences, Obstetrics & Reproductive Medicine, 32 Biomedical and clinical sciences, 42 Health sciences, 52 Psychology

Abstract:

The aim of this study was to establish the gynecological effects of 5 years of treatment with lasofoxifene versus placebo in postmenopausal osteoporotic women.